283 related articles for article (PubMed ID: 37278272)
1. Progress in Guillain-Barré syndrome immunotherapy-A narrative review of new strategies in recent years.
Yao J; Zhou R; Liu Y; Lu Z
Hum Vaccin Immunother; 2023 Aug; 19(2):2215153. PubMed ID: 37278272
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of Guillain-Barré syndrome.
Liu S; Dong C; Ubogu EE
Hum Vaccin Immunother; 2018; 14(11):2568-2579. PubMed ID: 29953326
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic strategies in the Guillain-Barré syndrome.
Kieseier BC; Hartung HP
Semin Neurol; 2003 Jun; 23(2):159-68. PubMed ID: 12894381
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin for Guillain-Barré syndrome.
Hughes RA; Swan AV; van Doorn PA
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD002063. PubMed ID: 25238327
[TBL] [Abstract][Full Text] [Related]
5. The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action.
Shahrizaila N; Yuki N
Expert Opin Pharmacother; 2011 Jul; 12(10):1551-60. PubMed ID: 21473704
[TBL] [Abstract][Full Text] [Related]
6. IVIG treatment and prognosis in Guillain-Barré syndrome.
van Doorn PA; Kuitwaard K; Walgaard C; van Koningsveld R; Ruts L; Jacobs BC
J Clin Immunol; 2010 May; 30 Suppl 1(Suppl 1):S74-8. PubMed ID: 20396937
[TBL] [Abstract][Full Text] [Related]
7. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology.
Hughes RA; Wijdicks EF; Barohn R; Benson E; Cornblath DR; Hahn AF; Meythaler JM; Miller RG; Sladky JT; Stevens JC;
Neurology; 2003 Sep; 61(6):736-40. PubMed ID: 14504313
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Guillain-Barré syndrome and CIDP.
van Doorn PA
J Peripher Nerv Syst; 2005 Jun; 10(2):113-27. PubMed ID: 15958124
[TBL] [Abstract][Full Text] [Related]
9. [Treatments and outcome predictors in Guillain-Barré syndrome].
Uchibori A; Chiba A
Nihon Rinsho; 2013 May; 71(5):845-9. PubMed ID: 23777092
[TBL] [Abstract][Full Text] [Related]
10. [Novel Therapeutic Interventions in Guillain-Barré Syndrome: Review and Future Perspective].
Misawa S
Brain Nerve; 2015 Nov; 67(11):1421-8. PubMed ID: 26560957
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immunoglobulin for Guillain-Barré syndrome.
Hughes RA; Swan AV; van Doorn PA
Cochrane Database Syst Rev; 2012 Jul; (7):CD002063. PubMed ID: 22786476
[TBL] [Abstract][Full Text] [Related]
12. Comparison on therapeutic effect of plasma exchange and intravenous immunoglobulin for Guillian-Barre syndrome.
Ye Y; Li SL; Li YJ
Transfus Med; 2015 Apr; 25(2):79-84. PubMed ID: 25515056
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of Guillain-Barré Syndrome].
Nomura K
Brain Nerve; 2015 Nov; 67(11):1397-410. PubMed ID: 26560955
[TBL] [Abstract][Full Text] [Related]
14. Advances in management of Guillain-Barré syndrome.
Doets AY; Jacobs BC; van Doorn PA
Curr Opin Neurol; 2018 Oct; 31(5):541-550. PubMed ID: 30074496
[TBL] [Abstract][Full Text] [Related]
15. Advances in the management of Guillain-Barré syndrome.
Green DM
Curr Neurol Neurosci Rep; 2002 Nov; 2(6):541-8. PubMed ID: 12359110
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for Guillain-Barré syndrome: a systematic review.
Hughes RA; Swan AV; Raphaël JC; Annane D; van Koningsveld R; van Doorn PA
Brain; 2007 Sep; 130(Pt 9):2245-57. PubMed ID: 17337484
[TBL] [Abstract][Full Text] [Related]
17. Functional outcomes following inpatient rehabilitation of Guillain-Barré syndrome patients: Intravenous immunoglobulins versus plasma exchange.
Bondi M; Engel-Haber E; Wolff J; Grosman-Rimon L; Bloch A; Zeilig G
NeuroRehabilitation; 2021; 48(4):543-551. PubMed ID: 34024788
[TBL] [Abstract][Full Text] [Related]
18. Guillain-Barré syndrome (GBS).
Pithadia AB; Kakadia N
Pharmacol Rep; 2010; 62(2):220-32. PubMed ID: 20508277
[TBL] [Abstract][Full Text] [Related]
19. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.
van Doorn PA; Ruts L; Jacobs BC
Lancet Neurol; 2008 Oct; 7(10):939-50. PubMed ID: 18848313
[TBL] [Abstract][Full Text] [Related]
20. Guillain-Barré syndrome: immunopathogenesis and therapeutic targets.
Liu S; Zhang WW; Jia L; Zhang HL
Expert Opin Ther Targets; 2024 Mar; 28(3):131-143. PubMed ID: 38470316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
